EANS-Adhoc: Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics AG announces changes in its Executive Management Board

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/molecular diagnostics

25.09.2012

Berlin, Germany, September 25, 2012 - The Supervisory Board of
Epigenomics AG (ISIN: DE000A1K0516) and its current CEO Geert Walter
Nygaard today agreed that Mr. Nygaard will leave the Executive
Management Board of the company effective 30 September 2012.

The current CFO, Dr. Thomas Taapken, thereby becomes the sole
Executive Board member of the company and this capacity also takes
over the responsibility of acting CEO of Epigenomics, effective 1
October 2012. Dr. Uwe Staub, currently SVP R&D was promoted to COO
and was granted "Prokura" (power of attorney). His duties will be
expanded by the responsibility for medical affairs and customer
support.

The Supervisory Board thanks Mr. Nygaard for his commitment and
contributions to Epigenomics over the last years.

- End of Ad hoc -

Contact Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com

Epigenomics' legal disclaimers. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

Further inquiry note:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386
antje.zeise@epigenomics.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: http://www.epigenomics.com
sector: Biotechnology
ISIN: DE000A1K0516
indexes: Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English